A Novartis medication aimed at treating heart failure could become a blockbuster, according to a company executive.
The medication, called Entresto, was released in 2015 and brought in $507 million revenue. But because demand for the drug could skyrocket, the company now predicts that Entresto will rake in about $4-$5 billion in annual revenue.
Blockbusters are defined as a drug that brings in at least $1 billion in annual sales.
Novartis also has the drug in a trial to see if it could become a treatment for preserved ejection fraction, another type of heart failure.
Read the full Reuters report.